Author + information
- Ali Pourdjabbar1,
- Lawrence Ang1,
- Paul T. Campbell2,
- Ryan D. Madder3,
- David H. Wohns3,
- Tomasz P. Stys4,
- Ronald Caputo5,
- Jeffrey Marshall6,
- Manish Parikh7,
- Vijaykumar Kasi8,
- Giora Weisz7 and
- Ehtisham Mahmud1
- 1UCSD, San Diego, CA
- 2Carolinas Health Care System, Concord, NC
- 3Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, MI
- 4Sanford Health, Sioux Falls, SD
- 5St. Joseph's Hospital Health Centre, Liverpool, NY
- 6Northeast Georgia Heart Centre, Gainesville, GA
- 7Columbia University, New York, NY
- 8Orlando Health Heart Institute, Orlando, FL
Limited data exist for robotic PCI outcomes via transradial access (TRA). The goal of this study was to compare clinical and technical success for radial- vs femoral access robotic PCI.
The multicenter PRECISION registry (n=11 sites) collected clinical and procedural data of robotic PCI procedures utilizing the CorPath 200 System (Corindus Vascular, Waltham, MA). Technical success was defined as procedural success (residual stenosis <30%; TIMI 3 flow) with robotic PCI while clinical success required absence of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, or clinically driven target vessel revascularization).
501 patients with 607 lesions were treated with robotic PCI with TRA in 310 (62%) and TFA in 191 (38%) patients. Technical success rates were 92.4% and 86.7% (TRA vs TFA), respectively (P=0.03) and clinical success rates were 99.4% and 94.7% respectively (P=0.002) (Table). Nine serious adverse events (SAE) (1.9% radial vs 1.6% femoral, p=1.0) unrelated to the CorPath 200 System occurred during the study period. Of these 9 SAEs, three (3) were determined MACE as defined by the protocol.
In this multicenter registry, robotic PCI was more commonly performed using radial rather than femoral access. Additionally transradial robotic PCI was found to be safe, with high rates of technical and clinical success.